Core Insights - AI-Media is showcasing its AI-powered subtitling and language solutions at ISE 2026, emphasizing the importance of real-time translation, captioning, and audio description in professional AV environments [1][2][4] Group 1: Company Overview - AI-Media is a global leader in AI-powered voice translation, captioning, and language orchestration, with a focus on modernizing workflows and enhancing communication [7] - The company offers the LEXI Suite, which includes solutions for real-time voice translation, subtitling, and audio description, aimed at delivering multilingual and accessible experiences [4][7] Group 2: Product Offerings - LEXI Voice is an AI-driven solution that provides real-time voice translation into any language with natural-sounding output and minimal delay, designed for live and broadcast environments [3] - LEXI Text is a real-time AI subtitling solution, while LEXI AD offers automated audio description, collectively supporting inclusive viewing experiences [4] Group 3: Industry Trends - The professional AV industry is moving towards expectations of reliability, low latency, and multilingual accessibility, similar to those in broadcasting [5] - AI-Media's solutions are positioned to help organizations create inclusive experiences from the outset, reflecting a broader industry shift towards inclusive communication as a standard expectation [5][6]

Company Overview - AIM ImmunoTech Inc. is a member of the Medical sector, which includes 931 individual stocks and currently holds a Zacks Sector Rank of 9 [2] - AIM ImmunoTech Inc. belongs to the Medical - Drugs industry, which consists of 141 individual stocks and is currently ranked 96 in the Zacks Industry Rank [5] Performance Analysis - AIM ImmunoTech Inc. has gained about 7.1% year-to-date, which matches the average return of Medical companies [4] - The Zacks Consensus Estimate for AIM's full-year earnings has increased by 3.8% over the past quarter, indicating improved analyst sentiment and a stronger earnings outlook [4] - In comparison, Cullinan Therapeutics, another Medical stock, has outperformed the sector with a year-to-date increase of 19.2% [4] Industry Comparison - The Medical - Drugs industry, to which AIM belongs, has seen an average gain of 3.5% this year, indicating that AIM is performing better than its industry peers [5] - Cullinan Therapeutics is part of the Medical - Biomedical and Genetics industry, which has moved up by 22.9% so far this year, and is currently ranked 94 [6]

OCALA, Fla., Jan. 27, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, announced today changes to the previously announced key dates relating to its proposed rights offering (the “Rights Offering”). Except as expressly amended herein, the terms of the Rights Offering remain unchanged. Assumin ...

Core Viewpoint - AIM ImmunoTech Inc. is conducting a proposed rights offering to raise gross proceeds of $12 million, which will be used for general corporate purposes, including clinical trial expenses and debt repayment [1][5]. Rights Offering Details - The rights offering will provide one non-transferable subscription right for each share of common stock and certain options and warrants held as of the record date of February 4, 2026 [2]. - Each subscription right allows the purchase of one unit at a subscription price of $1,000, with each unit consisting of one share of Series G Convertible Preferred Stock and warrants to purchase 1,492 shares of common stock [2]. - The subscription rights are non-transferable and can be exercised from February 5, 2026, to February 23, 2026, unless extended by the company [3][6]. Leadership Participation - Certain members of AIM's leadership, including CEO Thomas K. Equels, have indicated a non-binding intention to participate in the rights offering [4]. Use of Proceeds - The net proceeds from the rights offering will be allocated for clinical trial expenses related to Phase 2/3 pancreatic cancer trials and to repay certain existing debt obligations [5]. Important Dates - Key dates for the rights offering include: - February 3, 2026: Ownership Day for stockholders of record - February 4, 2026: Record Date - February 5, 2026: Subscription Period Begins - February 23, 2026: Subscription Period Ends [7]. Information Distribution - Broadridge Corporate Issuer Solutions, LLC will mail rights certificates and a prospectus to holders of record starting on or about February 5, 2026 [8].

As filed with the Securities and Exchange Commission on January 23, 2026 Registration No. 333-292085 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 AIM ImmunoTech Inc. (I.R.S. Employer Identification Number) 2117 SW Highway 484 Ocala FL 34473 (352) 448-7797 (Address, including zip code, and telephone number, including area code, of registrant's principal executive offices) Thomas K. Equels Chief Executive Officer AIM ImmunoTech Inc. 2117 SW Highway 484 Oc ...

Company Overview - AIM ImmunoTech Inc. is a notable stock within the Medical sector, which consists of 932 individual stocks and ranks 6 in the Zacks Sector Rank [2] - The company currently holds a Zacks Rank of 2 (Buy), indicating a favorable outlook based on earnings estimates and revisions [3] Performance Analysis - AIM ImmunoTech Inc. has achieved a year-to-date return of approximately 14.2%, outperforming the average gain of 8.9% for Medical stocks [4] - The Zacks Consensus Estimate for AIM's full-year earnings has increased by 3.8% over the past quarter, reflecting improved analyst sentiment and a stronger earnings outlook [4] Industry Context - AIM ImmunoTech Inc. is part of the Medical - Drugs industry, which includes 141 companies and currently ranks 81 in the Zacks Industry Rank. This industry has seen an average gain of 4.3% year-to-date, further highlighting AIM's superior performance [6] - In comparison, another stock in the Medical sector, Alzamend Neuro, Inc., has a year-to-date return of 28.6% and belongs to the Medical - Biomedical and Genetics industry, which ranks 107 and has gained 21.9% year-to-date [5][7]

Core Viewpoint - Massimo Group will showcase its new 2026 product lineup at AIM Expo, emphasizing its expansion into higher-value powersports vehicles and electric utility products [1][5]. Product Offerings - The 2026 Sentinel Series will feature fully enclosed HVAC UTVs, while the MVR HVAC Pro Series will include electric carts designed for various applications [2][3]. - The Sentinel Series aims to enhance Massimo's premium UTV offerings with factory-installed heating and air conditioning, while the MVR HVAC Pro Series targets markets such as golf, NEV, municipal, security, and commercial uses [3]. Market Reception - The company has received strong early market feedback and pre-order interest for both the Sentinel Series and MVR HVAC Pro Series, which is expected to bolster dealer confidence ahead of the 2026 model year [3]. Dealer Engagement - AIM Expo serves as a platform for Massimo to connect with its dealer network and introduce new products, reflecting the company's focus on higher-value offerings that benefit both dealers and end-users [4]. - New dealer programs for 2026 will be presented, aimed at enhancing dealer profitability and long-term partnerships, including improved parts and service support, a dealer demo unit program, and rebate programs [4]. Industry Context - AIM Expo 2026 will gather various stakeholders from the powersports ecosystem, providing an opportunity for Massimo to showcase its 2026 lineup and dealer strategy [5].

Core Viewpoint - Premarket trading is showing notable activity with significant price movements indicating potential investment opportunities before the market opens [1] Group 1: Premarket Gainers - SMX (Security Matters) Public Limited Company (SMX) is up 39% at $22.80 [3] - Rubico Inc. (RUBI) has increased by 21% to $1.30 [3] - Aimei Health Technology Co., Ltd (AFJK) is up 19% at $76.80 [3] - Sable Offshore Corp. (SOC) has risen 19% to $10.81 [3] - Diginex Limited (DGNX) is up 18% at $4.95 [3] - Sidus Space, Inc. (SIDU) has increased by 18% to $3.71 [3] - SELLAS Life Sciences Group, Inc. (SLS) is up 16% at $4.40 [3] - Alchemy Investments Acquisition Corp 1 (ALCY) has risen 14% to $16.24 [3] - Greenidge Generation Holdings Inc. (GREE) is up 11% at $1.65 [3] - Enigmatig Limited (EGG) has increased by 5% to $5.52 [3] Group 2: Premarket Losers - Intelligent Bio Solutions Inc. (INBS) is down 11% at $8.48 [4] - ZW Data Action Technologies Inc. (CNET) has decreased by 11% to $1.20 [4] - Nuvve Holding Corp. (NVVE) is down 9% at $2.31 [4] - ESH Acquisition Corp. (ESHA) has fallen 8% to $17.59 [4] - LZ Technology Holdings Limited (LZMH) is down 6% at $1.55 [4] - Oriental Rise Holdings Limited (ORIS) has decreased by 4% to $1.43 [4] - Cango Inc. (CANG) is down 3% at $1.45 [4] - Massimo Group (MAMO) has fallen 2% to $3.90 [4] - Anghami Inc. (ANGH) is down 2% at $3.68 [4] - AIM ImmunoTech Inc. (AIM) has decreased by 2% to $1.10 [4]

Core Viewpoint - AIM ImmunoTech Inc. announced a stock dividend of one share for every 1,000 shares of outstanding common stock and for every outstanding option or warrant that has a right to receive stock dividends, with the record date set for January 9, 2026, and distribution on January 13, 2026 [1]. Group 1: Stock Dividend Details - The stock dividend will be issued to stockholders and holders of Alternate Securities, with fractional shares rounded down and cash distributed for any remaining fractions based on a share price of $1.305, the average price on December 29, 2025 [2]. - Stockholders will not need to take any action to receive the stock dividend, as their accounts will be credited automatically, and brokers will receive the additional shares on behalf of stockholders [3]. Group 2: Company Overview - AIM ImmunoTech Inc. is focused on the research and development of therapeutics for various cancers, immune disorders, and viral diseases, including COVID-19, with its lead product being Ampligen (rintatolimod), a first-in-class investigational drug [4].

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...